×
About 1,865 results

ALLMedicine™ Huntington Disease Center

Research & Reviews  688 results

Circadian rhythms in neurodegenerative disorders.
https://doi.org/10.1038/s41582-021-00577-7 10.1007/s11065-021-09502-7 10.1007/s00415-020-10304-9 10.1523/ENEURO.0088-19.2019 10.1523/ENEURO.0431-17.2017
Nature Reviews. Neurology; Nassan M, Videnovic A

Nov 12th, 2021 - Endogenous biological clocks, orchestrated by the suprachiasmatic nucleus, time the circadian rhythms that synchronize physiological and behavioural functions in humans. The circadian system influences most physiological processes, including sleep...

Alternatives for Reducing Chorea in Huntington Disease
https://clinicaltrials.gov/ct2/show/NCT01897896

Nov 9th, 2021 - The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with...

Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A ...
https://doi.org/10.1212/WNL.0000000000012969
Neurology Delva A, Michiels L et. al.

Oct 20th, 2021 - Synaptic damage has been proposed to play a major role in the pathophysiology of Huntington's disease (HD), but in vivo evidence in humans is lacking. We performed a PET imaging study to assess synaptic damage and its clinical correlates in early ...

Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524312
JAMA Network Open; Coffey B, Jankovic J et. al.

Oct 19th, 2021 - Tourette syndrome is a neurodevelopmental disorder characterized by childhood onset of motor and phonic tics, often accompanied by behavioral and psychiatric comorbidities. Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  17 results

Alternatives for Reducing Chorea in Huntington Disease
https://clinicaltrials.gov/ct2/show/NCT01897896

Nov 9th, 2021 - The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with...

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
https://clinicaltrials.gov/ct2/show/NCT03980938

Aug 16th, 2021 - This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunc...

Decoding Presymptomatic White Matter Changes in Huntington Disease
https://clinicaltrials.gov/ct2/show/NCT03193099

Feb 18th, 2020 - WIN-HD is a monocentric longitudinal study comparing premanifest Huntingtin (HTT) mutation carriers and non HTT mutation carriers to determine that white-matter atrophy occurs far earlier than clinical onset in HD using Diffusion-weighted Nuclear ...

Resveratrol and Huntington Disease
https://clinicaltrials.gov/ct2/show/NCT02336633

Feb 5th, 2020 - Thanks to neuroimaging biomarkers already validated in HD and the newly identified metabolic brain biomarkers using 31P-MRS, we can test for a reduction in neurodegeneration among HD patients resulting from an improvement in brain energy profiles ...

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
https://clinicaltrials.gov/ct2/show/NCT01850381

Aug 8th, 2019 - Background The investigational drug GM608 is a synthetic oligopeptide containing 6 amino acids with a sequence identical to one of the active sites of human Motoneuronotrophic factor (MNTF), also referred to as GM6 in studies. MNTF is a novel huma...

see more →

News  38 results

Synthetic Triglyceride Shows Potential in Huntington Disease
https://www.medscape.com/viewarticle/959381

Sep 23rd, 2021 - The synthetic medium-chain triglyceride triheptanoin has shown potential to restore brain energy and decrease caudate atrophy in Huntington disease, and improved motor function for up to a year, according to data presented at the International Con...

Discovery of Schizophrenia Gene Could Advance Research, Therapies
https://www.medscape.com/viewarticle/948198

Mar 26th, 2021 - Todd Lencz, PhD A new genetic mutation in schizophrenia that blocks neuron communication in the brain may lead to novel treatment strategies and improve understanding of the mechanics of this disease. The discovery of this new gene, PCDHA3, could ...

Discovery of schizophrenia gene could advance research, therapies
https://www.mdedge.com/psychiatry/article/237694/schizophrenia-other-psychotic-disorders/discovery-schizophrenia-gene-could
Jennifer Lubell

Mar 25th, 2021 - A new genetic mutation in schizophrenia that blocks neuron communication in the brain may lead to novel treatment strategies and improve understanding of the mechanics of this disease. Dr.

Posttraumatic Stress Disorder-Associated Cognitive Deficits on the Repeatable Battery for the Assessment of Neuropsychological Status in a Veteran Population
https://www.mdedge.com/fedprac/article/234319/ptsd
Nathan Hantke, PhD, ABPP-CN*, Maheen M. Adamson, PhD* et. al.

Jan 7th, 2021 - Posttraumatic stress disorder (PTSD) affects about 10 to 25% of veterans in the US and is associated with reductions in quality of life and poor occupational functioning. 1,2 PTSD is often associated with multiple cognitive deficits that play a rol.

Certifying Medical Cannabis: What APRNs Need to Know
https://www.medscape.com/viewarticle/943249

Jan 5th, 2021 - A patient asks an advanced practice registered nurse (APRN) to approve them for "medical marijuana." What are the clinician's responsibilities? The first hurdle is legal. In 18 states, an APRN has the legal authority to certify a patient to use ma...

see more →

Patient Education  1 results see all →